Compare PCH & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCH | FOLD |
|---|---|---|
| Founded | 1903 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | N/A | 2007 |
| Metric | PCH | FOLD |
|---|---|---|
| Price | $40.80 | $9.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $45.67 | $30.29 |
| AVG Volume (30 Days) | 508.7K | ★ 4.2M |
| Earning Date | 01-26-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 312.61 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,115,571,000.00 | $598,704,000.00 |
| Revenue This Year | $3.38 | $21.49 |
| Revenue Next Year | $1.91 | $18.25 |
| P/E Ratio | $49.63 | ★ N/A |
| Revenue Growth | 5.40 | ★ 21.28 |
| 52 Week Low | $36.82 | $5.51 |
| 52 Week High | $48.12 | $10.57 |
| Indicator | PCH | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 60.26 |
| Support Level | $39.02 | $9.73 |
| Resistance Level | $40.14 | $10.05 |
| Average True Range (ATR) | 0.94 | 0.33 |
| MACD | 0.24 | -0.04 |
| Stochastic Oscillator | 69.86 | 40.87 |
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.